Importantly, the genetic or pharmacologic inhibition of PFKFB3 promoted tumor blood vessel normalization, a newer concept in adjuvant cancer therapy that aims to restore vessel perfusion and improve chemotherapy efficacy [20]. The gene discussed is PFKFB3; the disease is cancer.